Abstract Number: 69 • 2019 ACR/ARP Annual Meeting
Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by a type I Interferon (IFN-I) gene signature in peripheral blood lymphocytes (PBL), which contain enlarged mitochondria and…Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…Abstract Number: 697 • 2019 ACR/ARP Annual Meeting
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Background/Purpose: Although SLE disproportionately affects minority racial groups, this population is significantly under-represented in clinical trials, increasing risk for underpowered, incorrect conclusions in race-based sub-group…Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…Abstract Number: 1147 • 2019 ACR/ARP Annual Meeting
Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with a high rate of hospitalizations and is the sixth highest reason for 30-day readmissions among all medical…Abstract Number: 1580 • 2019 ACR/ARP Annual Meeting
Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Background/Purpose: Development of comorbidity over time in patients with systemic lupus erythematosus (SLE) is not well characterized. To provide a detailed and comprehensive picture hereof,…Abstract Number: 1620 • 2019 ACR/ARP Annual Meeting
T-cell Exhaustion in Prolonged Remission SLE Patients
Background/Purpose: Cellular exhaustion is a cellular dysfunction characterized by the progressive loss of the effector function, and an increased expression of multiple inhibitory receptors. Exhaustion…Abstract Number: 1851 • 2019 ACR/ARP Annual Meeting
The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus
Background/Purpose: African Americans (AA) are more likely to experience psychosocial and environmental stressors and develop SLE than whites. Increasing frequency of racial discrimination is associated…Abstract Number: 2043 • 2019 ACR/ARP Annual Meeting
Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation
Background/Purpose: Arthritis is a common clinical feature of systemic lupus erythematosus (SLE), that can be present either at the onset or in later disease course.…Abstract Number: 2523 • 2019 ACR/ARP Annual Meeting
Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
Background/Purpose: SLE is a complex illness that can be associated with chronic pain. In recent years, an international opioid epidemic has become a major public…Abstract Number: 2559 • 2019 ACR/ARP Annual Meeting
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
Background/Purpose: Anifrolumab is a fully human, IgG1κ monoclonal antibody that binds to the type I IFN receptor and inhibits activity of all type I IFNs.1…Abstract Number: 2792 • 2019 ACR/ARP Annual Meeting
The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis
Background/Purpose: Autoimmune Connective Tissue Disorders (CTDs), including Mixed Connective Tissue Disorders (MCTD), systemic sclerosis (SSc) and systemic lupus erythematous (SLE) can lead to Raynaud phenomenon,…Abstract Number: 73 • 2019 ACR/ARP Annual Meeting
Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome
Background/Purpose: 6-gingerol, the major bioactive compound of ginger root, is known to have anti-inflammatory and anti-oxidative effects. Indeed, ginger has been employed for millennia as…Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…Abstract Number: 700 • 2019 ACR/ARP Annual Meeting
Sleep Quality Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Poor sleep quality is a frequent concern among patients with systemic lupus erythematosus (SLE) and contributes to fatigue and other comorbidities. This study investigates…
- « Previous Page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- …
- 150
- Next Page »